HCT Consolidation Improves Survival in Younger MCL Patients
This video highlights results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant during first remission.
In this video, Brian T. Hill, MD, PhD, of the Cleveland Clinic in Ohio, discusses results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant (HCT) during first remission.
Results of the study (abstract 341) were presented last week at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
